Dossier - Page 1 - FirstWord Reports

Learn More Charting Real World Data and Evidence - Activity and Capabilities (2018)

How do Real World Data (RWD) and Real World Evidence (RWE) professionals see their critical role developing? Which teams are using RWD/RWE, where is it providing most value and how might this change over the next 2...

Compare
Learn More Time to Market: Accelerating Market Access

Building the most effective strategy for fast track market access Getting to market faster clearly has benefits, but there are also potential downsides for drug companies too. You need to know the options and consider...

Compare
Learn More Virtual Clinical Trials: The future of drug development?

How viable are virtual clinical trials as a model for conducting clinical research? With our deepening understanding of disease and ever more targeted therapies, slow and costly traditional clinical trials alone are no...

Compare
Learn More A new Era in Pharma Marketing: Delivering Content-Driven Experiences

Are you locked in a traditional product marketing mind set? Time to move on... How can you provide better support and awareness to HCPs and patients for your brands? Content marketing may be the answer. Advocates argue...

Compare
Learn More Medical-grade Wearable Technology: Applications and implications for pharma

Leveraging clinical wearables and digiceuticals to gain competitive advantage From smart wristbands and glasses to tiny sensors in pills, the latest advances in medical-grade technology are unlocking new opportunities...

Compare
Learn More Biologics Life Cycle Management: Tactics and Strategies in the Biosimilars Era

The biologics competitive landscape is at a critical stage of development. How will you respond? Biosimilars are on the offensive across Europe and beyond. With the recent launches of multiple new biosimilars to compete...

Compare
Learn More Pharma-patient engagement: Patient centricity comes of age

Are you truly patient-centric or just ticking boxes? Find out how your strategy compares Until relatively recently, patient centricity was commonly seen as just a useful talking point and the catalyst for some...

Compare
Learn More The MSL Technology Survey (2018)

How is technology changing the face of MSL/KOL interaction and which technologies are set to take a greater role is this critical relationship? Which technologies are being employed to identify KOLs? What technology...

Compare
Learn More Artificial Intelligence and Machine Learning: Applications in Pharma

Where can Artificial Intelligence and Machine Learning really drive change in pharma's business? Artificial Intelligence (AI) and Machine Learning (ML) have the potential to unlock new insights and massively improve...

Compare
Learn More Orphan Drugs: US Payer Perspectives

So what will persuade US payers to better support orphan drugs? US payer concern at the number of new orphan drugs coming to market, often with eye watering prices attached, can obscure a more positive message: payers...

Compare
Learn More Orphan Drugs: European Payer Perspectives

European payers reveal how pharma can build trust and gain their support for orphan drug products European payers are concerned about orphan drugs citing unjustified high prices and a lack of evidence of utility and...

Compare
Learn More Do Payers Really Want Pay-for-Performance?

Explore the latest payer views and requirements for pay for performance When it comes to payment for performance (P4P), it's notoriously difficult to know exactly what payers want to see. Useful face-to-face payer...

Compare
Learn More Voice Assistants and Medical Chatbots in Healthcare

Voice activated technology: What are the potential benefits for pharma? The use of voice-controlled assistants (VCAs) such as Apple's Siri and Amazon's Alexa are familiar to many of us in our daily lives. But how might...

Compare
Learn More Patient Journey Mapping for Market Access

Which market access teams will be first to unlock the power of patient journey mapping? There's no doubt that market access has evolved significantly in recent years, but there is so much more to be done. What some...

Compare
Learn More Benchmarking Pharma’s Digital Marketing Capabilities

Pharma is behind the curve in digital marketing. What does the industry need to do to fully release the power of digital communications? Driven by customer demand, digital marketing has grown in importance and is now...

Compare
Learn More Biosimilars in Emerging Markets (2018)

Biosimilars: Evaluating opportunities and risks in emerging markets Are you seeking new opportunities for biosimilars? The potential in emerging markets remains attractive, however the high-profile BRIC countries - and...

Compare
Learn More Gene Therapy: Commercial Opportunities and Challenges for Pharma

As gene therapies for major diseases accelerate from the development pipeline, how can pharma exploit near-term opportunities and protect its business going forward? As gene therapies for major diseases accelerate from...

Compare
Learn More Payer Engagement: Benchmarking team structure and activity

Benchmark your payer engagement team's performance against the industry's best! Winning payer support to secure reimbursement and optimum pricing is a battle payer engagement teams' face daily. But in the face of ever...

Compare
Learn More Digital Therapeutics: Taking digital health to a new level

The Digital Therapeutics field is exploding: what does pharma need to know - and do - to get on board? Evidence-based and reimbursed digital therapeutics (DTx) are now part of the health delivery landscape. They hold...

Compare
Learn More Blockchain: Transformational change for Pharma?

Is blockchain really the technology that can revolutionise pharma's business? Rapidly developing Blockchain technology can deliver transparent, secure and reliable data sharing. It also has the prospect of streamlining...

Compare

Browse by